Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer

References

• ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–2
   PubMed Web of Science ®Google Scholar
• Thurlimann B, Keshaviah A, Coates A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–57
   PubMed Web of Science ®Google Scholar
• Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005;23:5138–47
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366: 455–62
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–802
   PubMed Web of Science ®Google Scholar
• Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 2005;23:10s [abstract 527]
   Google Scholar
• Voogd AC, van Oost FJ, Rutgers EJ, et al. Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer 2005;41:2637–44
   PubMed Web of Science ®Google Scholar
• Willner J, Kiricuta IC, Kolbl O, et al. Long-term survival following postmastectomy locoregional recurrence of breast cancer. Breast 1999;8:200–4
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Blumenschein GR, Smith TL, et al. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol 1979;12:27–40
   PubMed Web of Science ®Google Scholar
• Fortin A, Larochelle M, Laverdiere J, et al. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 1999;17:101–9
   PubMed Web of Science ®Google Scholar
• Lamerato L, Havstad S, Gandhi A, et al. Costs of initial, continuing and terminal care in US patients with recurrence following early breast cancer. J Clin Oncol 2005;23:37s [abstract 634]
   Google Scholar
• Houghton J: ATAC Trialists’ Group. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial. J Clin Oncol 2005;23:24s [abstract]
   Google Scholar
• Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738–46
   Google Scholar
• Jakesz R, Gnant M, Greil R, et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 2005;94:S10 [abstract 13]
   Google Scholar
• Punglia RS, Kuntz KM, Winer EP, et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 2005;23:5178–87
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Cuzick J. Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer. J Clin Oncol 2005;23:8544–6
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006;94:460–4
   Google Scholar
• Viale G, Regan M, Dell’Orto B, et al. Central review of ER, PgR and HER-2 in BIG 1–98 evaluating letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2005;94:S13 [abstract 44]
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684–90
   PubMed Web of Science ®Google Scholar
• The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131–9
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512–7
   PubMed Web of Science ®Google Scholar
• Cuzick J. Forest plots and the interpretation of subgroups. Lancet 2005;365:1308
   PubMed Web of Science ®Google Scholar
• Duffy SR, Distler W, on behalf of the ATAC Trialists’ Group. Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: results from the ATAC trial. Breast Cancer Res Treat 2005;94:S102 [abstract 2056]
   Google Scholar
• Goss PE, Ingle JN, Palmer MJ, et al. Updated analysis of NCIC CTG MA 17 (letrozole vs placebo to letrozole vs placebo) post unblinding. Breast Cancer Res Treat 2005;94(Suppl 1):S10–11 [abstract 16]
   Google Scholar
• Ismail AA, Pye SR, Cockerill WC, et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study. Osteoporos Int 2002;13:565–71
   PubMed Web of Science ®Google Scholar
• Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–57
   PubMed Web of Science ®Google Scholar
• Howell A, on behalf of the ATAC Trialists’ Group. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in post-menopausal women with early breast cancer – updated efficacy results based on a median follow-up of 5 years [online]. Available from http://209.196.53.174/2004 [Last accessed June 2006]
   Google Scholar
• World Health Organization. Technical report series 843. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: WHO Press, 1994. Available from http://www.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=10&codcch=843# [Last accessed June 2006]
   Google Scholar
• Eastell R. Effect of anastrozole of bone mineral density: 2 year results of the Arimidex (anastrozole) Tamoxifen, Alone or in combination (ATAC) trial. American Society for Bone and Mineral Research 25th Annual Meeting, Minneapolis, Minnesota, USA, 19–23 September 2003
   Google Scholar
• Chlebowski RT. Bone health in women with early-stage breast cancer. Clin Breast Cancer 2005;5:S35–40
   Google Scholar
• Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006;33:13–7
   PubMed Web of Science ®Google Scholar
• Garber JE, Halabi S, Kaplan E, et al. Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen. Proc ASCO 2005;23:6s [abstract 508]
   Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Cushman M, Costantino JP, Tracy RP, et al. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 2001;21:255–61
   PubMed Web of Science ®Google Scholar
• Bagdade JD, Wolter J, Subbaiah PV, et al. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 1990;70:1132–5
   PubMed Web of Science ®Google Scholar
• Sawada S, Sato K, Kusuhara M, et al. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer. Acta Oncol 2005;44:134–41
   PubMed Web of Science ®Google Scholar
• McCloskey E, Eastell R, Lakner G, et al. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res Treat 2005;94:S101 [abstract 2052]
   Google Scholar
• Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937–47
   PubMed Web of Science ®Google Scholar
• Howell A, on behalf of the ATAC Trialists’ Group. ATAC trial update – authors’ reply. Lancet 2005;365:1225–6
   Google Scholar
• Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA 17. J Natl Cancer Inst 2005;97:1262–71
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–88
   PubMed Web of Science ®Google Scholar
• Duggan C, Marriott K, Edwards R, et al. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003;21:3588–93
   PubMed Web of Science ®Google Scholar
• Howell A. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer – updated efficacy results based on a median follow-up of 5 years. Breast Cancer Res Treat 2004;88 (Suppl 1):S7 [abstract 1]
   Google Scholar